Protea Biosciences Group Inc (PRGBQ) financial statements (2021 and earlier)

Company profile

Business Address 1311 PINEVIEW DRIVE
MORGANTOWN, WV 26505
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments000 0 
Cash and cash equivalents000 0 
Receivables000000
Inventory, net of allowances, customer advances and progress billings000000
Inventory000000
Prepaid expense000000
Total current assets:101110
Noncurrent Assets
Property, plant and equipment222332
Other noncurrent assets000000
Total noncurrent assets:222332
TOTAL ASSETS:333343
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities220222
Accounts payable120211
Accrued liabilities000000
Employee-related liabilities000000
Taxes payable  0   
Interest and dividends payable000000
Debt444442
Due to related parties213333
Deferred revenue and credits000000
Other liabilities   11 
Other undisclosed current liabilities5108714
Total current liabilities:131716171010
Noncurrent Liabilities
Long-term debt and lease obligation, including:222222
Long-term debt, excluding current maturities    3 
Other undisclosed long-term debt and lease obligation2222(1)2
Other undisclosed noncurrent liabilities    3 
Total noncurrent liabilities:222252
Total liabilities:151917191512
Stockholders' equity
Stockholders' equity attributable to parent(12)(16)(14)(16)(11)(9)
Common stock000000
Additional paid in capital958581727271
Accumulated other comprehensive income (loss)0000(0)0
Accumulated deficit(107)(101)(95)(88)(82)(81)
Total stockholders' equity:(12)(16)(14)(16)(11)(9)
TOTAL LIABILITIES AND EQUITY:333343

Income statement (P&L) ($ in millions)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
Revenues
(Revenue, Net)
001110
Cost of revenue(0)(0)(1)(0)(0)(0)
Gross profit:(0)00000
Operating expenses(1)(2)(1)(2)(2)(2)
Operating loss:(1)(2)(1)(1)(1)(2)
Nonoperating income (expense)(4)(4)(6)(4)(0)0
Interest and debt expense(8)(0)(0)(1)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(14)(6)(8)(6)(2)(1)
Other undisclosed income from continuing operations before income taxes800100
Net loss available to common stockholders, diluted:(6)(6)(7)(6)(2)(1)

Comprehensive Income ($ in millions)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
Net loss:(6)(6)(7)(6)(2)(1)
Comprehensive loss:(6)(6)(7)(6)(2)(1)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00 0(0)0
Comprehensive loss, net of tax, attributable to parent:(6)(6)(7)(6)(2)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: